Európska únia - slovenčina - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - verteporfín - myopia, degenerative; macular degeneration - oftalmologiká - visudyne je indikovaný na liečbu:dospelí s exudative (mokré) vekom podmienená makulárna degenerácia (amd) s prevažne klasické subfoveal choroidal neovascularisation (cnv) alebo;dospelí s subfoveal choroidal neovascularisation sekundárne na patologické krátkozrakosť.

Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - oftalmologiká - lucentis je indikovaný u dospelých na:liečbu neovascular (mokré) vekom podmienená makulárna degenerácia (amd)liečbe zraku v dôsledku choroidal neovascularisation (cnv)liečbe zraku v dôsledku diabetickej makulárnej edém (dme)liečbe zraku v dôsledku makulárnej edém stredoškolské do žily sietnice occlusion (pobočka rvo alebo strednej rvo).

Európska únia - slovenčina - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologiká - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Európska únia - slovenčina - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiká - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Európska únia - slovenčina - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiká - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Európska únia - slovenčina - EMA (European Medicines Agency)

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - oftalmologiká - eylea je indikovaný u dospelých na liečbu:neovascular (mokré) vekom podmienená makulárna degenerácia (amd);zraku v dôsledku makulárnej edém stredoškolské do žily sietnice occlusion (pobočka rvo alebo strednej rvo);zraku v dôsledku diabetickej makulárnej edém (dme);zraku v dôsledku krátkozrakého choroidal neovascularisation (krátkozrakého cnv).

Európska únia - slovenčina - EMA (European Medicines Agency)

pharmaswiss ceska republika s.r.o - pegaptanibu - wet macular degeneration - oftalmologiká - macugen je indikovaný na liečbu neovaskulárnej (mokrej) vekom podmienenej makulárnej degenerácie (amd).

Európska únia - slovenčina - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmologiká - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.